Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia. Dashdorj, Wirz, Röltgen et. al

Published: 4 November 2021| Version 1 | DOI: 10.17632/hy3zm69f57.1
Contributors:
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,

Description

Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins reveal marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide. Demographic data and electrochemiluminescence data are shared in this data file.

Files

Steps to reproduce

Two electrochemiluminescence assays were performed in this study. (1) IgG antibodies targeting the Wuhan-Hu1 SARS-CoV-2 nucleocapsid (N), spike (S) and spike receptor binding domain (RBD) were detected using MSD V-PLEX Coronavirus Panel 4 (IgG) kits (Meso Scale Discovery) according to the manufacturer protocols. (2) Antibodies blocking the binding of ACE2 protein to SARS-CoV-2 RBD for viral variants Alpha (N501Y), Beta (K417N, E484K, N501Y), Gamma (K417T, E484K, N501Y), Delta (L452R, T478K), Epsilon (L452R), Eta/Iota/Zeta (E484K), Kappa (L452R, E484Q), B.1.526.2 (S477N) and P.3 (E484K, N501Y), and Wuhan-Hu1 were detected with MSD V-PLEX SARS-CoV-2 Panel 11 (ACE2) kits according to the manufacturer’s protocols. This data set includes the electrochemiluminescence data from both assays. Detailed methods were described in Dashdorj NJ, Wirz OF, Röltgen K et al. (2021) Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia. doi: https://doi.org/10.1101/2021.08.22.21262161.

Institutions

Onom Foundation, Stanford University School of Medicine, Meso Scale Diagnostics LLC

Categories

Vaccine, Infectious Disease Serology, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

License